Principal Financial Group Inc. increased its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 0.9% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,686,453 shares of the medical equipment provider’s stock after buying an additional 14,795 shares during the period. Principal Financial Group Inc.’s holdings in Boston Scientific were worth $105,825,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also bought and sold shares of BSX. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp grew its stake in Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors grew its stake in Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank bought a new position in Boston Scientific in the fourth quarter worth about $2,199,395,000. Finally, Morgan Stanley raised its holdings in Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.
More Boston Scientific News
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Analysts still see meaningful upside in Boston Scientific despite near-term concerns, with one note highlighting a bullish rating and a price target that remains well above the current share price. Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside
- Neutral Sentiment: Boston Scientific was mentioned in a broader large-cap stock roundup, but the article did not add any new company-specific catalyst. 1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
- Negative Sentiment: Management commentary pointed to a slowdown in WATCHMAN, and Needham lowered its price target to $57 from $77, signaling reduced optimism about near-term growth. Boston Scientific (BSX) Faces WATCHMAN Slowdown But Analysts Still See Upside
- Negative Sentiment: The company recently initiated voluntary Class II recalls of CRE and CRE Pro Wireguided endoscopy devices worldwide due to potential sterile packaging breaches, increasing quality and regulatory risk. Are Boston Scientific’s (BSX) Sterile-Packaging Recalls Reframing the Narrative on Quality and Regulatory Risk?
- Negative Sentiment: Recent coverage also noted that Boston Scientific stock fell in the latest session despite broader market gains, reinforcing investor concerns about momentum and execution. Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note
Analysts Set New Price Targets
Get Our Latest Research Report on BSX
Boston Scientific Trading Up 1.0%
NYSE BSX opened at $43.08 on Thursday. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a fifty day simple moving average of $48.62 and a two-hundred day simple moving average of $66.39. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market cap of $64.02 billion, a P/E ratio of 18.02, a P/E/G ratio of 0.82 and a beta of 0.58.
Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same period in the previous year, the company earned $0.75 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.
Boston Scientific announced that its board has approved a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.
Insiders Place Their Bets
In other news, Director David C. Habiger purchased 2,250 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by company insiders.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
